- Home
- AEVA vs TLSI Comparison
AEVA vs TLSI Comparison
Compare AEVA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEVA | TLSI |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEVA | TLSI |
|---|---|---|
| Price | $13.34 | $6.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $26.50 | $11.50 |
| AVG Volume (30 Days) | ★ 2.0M | 215.2K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,154,000.00 | ★ $40,207,000.00 |
| Revenue This Year | $87.44 | $55.06 |
| Revenue Next Year | $70.13 | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 89.90 | 49.52 |
| 52 Week Low | $2.52 | $3.42 |
| 52 Week High | $38.80 | $7.95 |
Technical Indicators
Market Signals| Indicator | AEVA | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 55.25 |
| Support Level | $12.83 | $6.61 |
| Resistance Level | $15.73 | $7.95 |
| Average True Range (ATR) | 1.12 | 0.43 |
| MACD | -0.15 | -0.14 |
| Stochastic Oscillator | 14.07 | 22.76 |
Price Performance
Historical ComparisonAbout AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.